147 A Prospective Phase II, Open-Label, Single-arm, Multicenter Study to Assess the Efficacy and Safety of SEG101 (Crizanlizumab) in Sickle Cell Disease Patients With Priapism (SPARTAN).
Saved in:
| Title: | 147 A Prospective Phase II, Open-Label, Single-arm, Multicenter Study to Assess the Efficacy and Safety of SEG101 (Crizanlizumab) in Sickle Cell Disease Patients With Priapism (SPARTAN). |
|---|---|
| Authors: | Burnett, A.1 (AUTHOR), El Rassi, F.2 (AUTHOR), Darbari, D.3 (AUTHOR), Paulose, J.4 (AUTHOR), Lainé, D.4 (AUTHOR), Purkayastha, D.5 (AUTHOR), Kato, G.6 (AUTHOR) |
| Source: | Journal of Sexual Medicine. 2020 Supplement 1, Vol. 17, pS43-S43. 1p. |
| Database: | Academic Search Ultimate |
Be the first to leave a comment!
